Eli Lilly and Company (NYSE:LLY) Shares Bought by Cahaba Wealth Management Inc.

Cahaba Wealth Management Inc. boosted its stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,536 shares of the company’s stock after buying an additional 24 shares during the quarter. Cahaba Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $895,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. JGP Wealth Management LLC lifted its stake in Eli Lilly and Company by 0.9% in the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after acquiring an additional 16 shares during the last quarter. Cassia Capital Partners LLC lifted its stake in shares of Eli Lilly and Company by 1.8% in the third quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock worth $511,000 after buying an additional 17 shares during the last quarter. Walkner Condon Financial Advisors LLC lifted its stake in shares of Eli Lilly and Company by 2.8% in the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after buying an additional 17 shares during the last quarter. Patton Albertson Miller Group LLC lifted its stake in shares of Eli Lilly and Company by 2.8% in the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after buying an additional 17 shares during the last quarter. Finally, Valley Wealth Managers Inc. lifted its stake in shares of Eli Lilly and Company by 1.3% in the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after buying an additional 17 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on LLY. Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Barclays boosted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Bank of America boosted their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $700.00.

View Our Latest Report on Eli Lilly and Company

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $3.41 on Tuesday, hitting $763.96. The company’s stock had a trading volume of 2,552,667 shares, compared to its average volume of 3,221,156. The firm has a market cap of $725.88 billion, a P/E ratio of 131.72, a price-to-earnings-growth ratio of 1.71 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company has a fifty day moving average price of $739.63 and a 200-day moving average price of $641.00. Eli Lilly and Company has a one year low of $342.30 and a one year high of $800.78.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter in the prior year, the firm earned $2.09 EPS. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 195,055 shares of company stock valued at $125,254,657. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.